[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"implant-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:implant-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,69,99,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100521855","biofilm-accumulation-in-zirconia-vs-titanium-implants-100521855",false,"NCT06075017","Biofilm Accumulation in Zirconia vs. Titanium Implants","Comparison of Biofilm Accumulation on the Surface of Zirconia Versus Titanium Implants. Randomized Controlled Pilot Clinical Trial","Inclusion Criteria:\n\n* Patients of both sexes of legal age.\n* Patients ASA I, II and III.\n* Subsequent to the placement of a single implant.\n* Patients who accept the surgery and sign the informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients who cannot attend follow-up appointments after surgery.\n* Patients with implants adjacent to the area to be treated.\n* Patients with uncontrolled periodontal pathology.\n* Systemic pathology that contraindicates the surgical procedure: hepatitis or other infectious diseases, oncological treatment, untreated or uncontrolled systemic pathology: diabetes mellitus, arterial hypertension, osteoporosis, heart failure, valvular heart disease, history of endocarditis, acute myocardial infarction less than 6 months ago, stroke less than 6 months ago, history of venous thromboembolism, arrhythmias, vitamin D deficiency, Parkinson's and Alzheimer's disease, dementia, psychiatric disorders, liver disease, COPD, chronic renal failure, immunosuppressed, autoimmune diseases, inflammatory bowel disease, digestive pathology, phosphocalcium metabolism diseases, hyper- or hypothyroidism, endocrinopathies, celiac disease, collagenosis, etc.\n* Pharmacological treatment with anticoagulants, antiaggregants, bisphosphonates, monoclonal antibodies, serotonin reuptake inhibitors, immunosuppressants, corticosteroids, antipsychotics.",true,"ALL","18 Years","99 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this randomized clinical trial is to compare the amount and type of biofilm formed on the surface of zirconia implants compared to titanium implants.\n\nA pilot randomized clinical trial will be conducted in which 15 zirconia and 15 titanium single implants will be placed in different patients and the amount of total biofilm and different bacterial species will be evaluated at 3, 6 and 12 months after placement, in addition to bleeding on probing, plaque index, amount of keratinized gingiva, marginal bone loss and patient satisfaction. The Shapiro-Wilk normality test will be performed to determine whether each group follows a normal distribution. Once the distribution of the samples has been verified, we will proceed to apply a parametric test of repeated measures ANOVA or mixed ANOVA with Bonferroni correction, in order to observe what changes exist in the variables to be studied and if these will be statistically significant, establishing a significance level of P\\\u003C0.05. If the distribution does not comply with normality, the nonparametric Friedman test will be performed.",[28],"Implant Infection","RECRUITING","2026-05-04",{"date":32,"type":33},"2026-05-08","ACTUAL",{"date":35,"type":22},"2027-12-01",{"date":37,"type":22},"2028-12-01",{"name":39,"class":40},"Universidad Complutense de Madrid","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100633946","phase-3-bacteriophage-therapy-for-orthopedic-implant-associated-infections-100633946","NCT07533292","Bacteriophage Therapy for Orthopedic Implant-Associated Infections","Prospective, Single-Center, Single-Arm, Pre-Post Self-Controlled Study Evaluating the Efficacy and Safety of Bacteriophage Therapy in Orthopedic Implant-Associated Infections","Inclusion Criteria:\n\n* Known allergy or hypersensitivity to bacteriophages or any components of the bacteriophage preparation;\n* Pregnant or breastfeeding women;\n* Participation in another interventional clinical trial within the study period;\n* Lack of feasible routes of administration other than intravenous injection;\n* Patients deemed unsuitable for participation in this study by the investigator;\n* Inability or unwillingness of the subject to comply with study procedures.\n\nExclusion Criteria:\n\n* Withdrawal of informed consent by the participant at any time during the study;\n* Occurrence of serious adverse events related to bacteriophage therapy that, in the investigator's judgment, necessitate discontinuation of treatment.",{"count":50,"type":22},100,[52],"PHASE3","A Prospective, Single-Center, Single-Arm Clinical Study with a Pre-Post Self-Controlled Design Evaluating the Efficacy and Safety of Bacteriophage Therapy for Refractory Orthopedic Implant-Associated Infections",[55,28],"Orthopedic",[57,58],"Bacteriophage Therapy","Orthopedic Implant-Associated Infections","NOT_YET_RECRUITING","2026-04-09",{"date":62,"type":33},"2026-04-16",{"date":64,"type":22},"2026-04-05",{"date":66,"type":22},"2030-12-31",{"name":68,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":77,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100418616","phase-3-local-antibiotics-for-breast-implants-100418616","NCT04731025","Local Antibiotics for Breast Implants","Prophylactic Treatment of Breast Implants With a Solution of Gentamicin, Vancomycin and Cefazolin Antibiotics for Women Undergoing Breast Reconstructive Surgery: a Randomized Controlled Trial (The BREAST-AB Trial)","BREAST-AB","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Biologically female\n* Signed informed consent\n* Scheduled for breast reconstruction with implants or expanders including:\n\n  1. Immediate or delayed reconstructions\n  2. Bilateral or unilateral reconstructions\n  3. With or without simultaneous flap reconstruction\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast feeding\n* Known allergy towards Vancomycin, Gentamicin and Cefazolin\n* Known anaphylactic reaction towards other beta-lactam antibiotics or aminoglycosides\n* Known allergy towards neomycin\n* Known impaired renal function with GFR \\\u003C 60 mL\u002Fmin\n* Participation in investigational drug trials and projects concerning disinfecting agents in the breast implant cavity\n* Myasthenia Gravis","FEMALE",{"count":79,"type":22},1003,[52],"The BREAST-AB Trial is a multi-center, randomized, double blind, placebo-controlled trial investigating the efficacy of local application of gentamicin, vancomycin and cefazolin in decreasing all-cause implant explantation after breast reconstruction.",[83,28,84,85,86,87,88],"Implant Complication","Implant Site Infection","Implant Capsular Contracture","Implant Site Pocket Infection","Implant Expulsion","Antibiotic Side Effect","2026-02-09",{"date":91,"type":33},"2026-02-12",{"date":93,"type":33},"2021-01-27",{"date":95,"type":22},"2027-08",{"name":97,"class":40},"Mikkel Herly",8,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":77,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":41},"100566031","a-novel-surgical-irrigation-solution-in-post-mastectomy-reconstruction-evaluating-xperience-100566031","NCT06649890","A Novel Surgical Irrigation Solution in Post-Mastectomy Reconstruction: Evaluating Xperience™","A Randomized Control Trial Evaluating the Efficacy of Xperience™ Surgical Irrigation Solution Versus Dilute Povidone-Iodine in Preventing Surgical Site Infections and Improving Postoperative Outcomes in Implant-Based Breast Reconstruction","Inclusion Criteria:\n\n* Older than 18 years old\n* Willing to comply with all study-related procedures\n* Available for the duration of the study\n* Participants undergoing double mastectomy surgery followed by one of the following: (1) Immediate reconstruction with tissue expander placement, (2) Delayed reconstruction with tissue expander or implant placement, (3) Immediate reconstruction with implant placement, (4) Second-stage reconstruction with tissue expander to implant exchange\n\nExclusion Criteria:\n\n* Participants unable to participate in follow-up visits\n* Participants undergoing unilateral mastectomy\n* Tissue expanders placed by a surgeon outside of the UNC Chapel Hill Hospital System\n* Undergoing autologous reconstruction\n* Participant is unable to provide signed and dated informed consent\n* Unwilling or unable to comply with all study-related procedures.\n* Known history of sensitivity or allergic reaction to any of the components of the Xperience™ irrigation solution or dilute povidone-iodine irrigation\n* Participant with any conditions that would be a contraindication to receiving surgery such as contraindications to general anesthesia\n* Pregnant, planning to become pregnant or breast feeding participants\n* Individuals providing informed consent with any mental impairment or condition that would make them unable to properly consent without use of legally authorized representative (LAR) or additional participant protections.\n* Incarcerated participants",{"count":107,"type":22},224,[25],"Goal of the Clinical Trial:\n\nThe purpose of this clinical trial is to learn whether Xperience™ surgical irrigation solution is more effective than a standard dilute povidone-iodine solution in reducing surgical site infections (SSIs) following implant-based breast reconstruction in female patients, aged 18 and older. It will also assess the safety and overall surgical outcomes when using Xperience™ compared to povidone-iodine.\n\nMain Questions the Study Aims to Answer:\n\n* Does the use of Xperience™ decrease the incidence of surgical site infections compared to povidone-iodine?\n* What are the differences in the rates of premature implant removal due to infection between patients treated with Xperience™ and those treated with povidone-iodine?\n* Are there fewer post-surgical complications with Xperience™ compared to povidone-iodine?\n\nStudy Design:\n\nParticipants in this study will be randomly assigned to receive either Xperience™ or a dilute povidone-iodine solution during their bilateral implant-based breast reconstruction. Only the research team will know which irrgiation is given- the participant will not know.\n\nParticipant Will:\n\n* Undergo the surgical procedure using one of the two irrigation solutions.\n* Receive regular post-operative check-ups to monitor for signs of infection and other complications.\n* Have data collected on any post-surgical complications, the necessity for early implant removal, and overall surgical outcomes.",[111,112,28,83],"Surgical Site Infection","Surgical Complication","2025-08-06",{"date":115,"type":33},"2025-08-07",{"date":117,"type":33},"2025-06-30",{"date":119,"type":22},"2028-06-30",{"name":121,"class":40},"University of North Carolina, Chapel Hill",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":41},"100441163","early-phase-1-antiseptic-effects-on-the-dental-implant-internal-surface-microbiome-100441163","NCT05024760","Antiseptic Effects on the Dental Implant Internal Surface Microbiome","Inclusion Criteria:\n\n* Active duty military\n* 18-55 years old\n* Over 6 months remaining at local duty station\n\nExclusion Criteria:\n\n* Tobacco user\n* Medications that affect soft tissue or bone healing\n* Metabolic disorder that affects soft tissue or bone healing\n* Active periodontal disease","55 Years",{"count":130,"type":22},150,[132],"EARLY_PHASE1","Soldiers operate in environments that are more likely to lead to oral trauma, risking poor dentition which can directly impact military readiness. Dental restoration can often be accomplished via dental implant insertion. Microbiome-associated complications that result in bone loss, including the micro-leakage of bacterial species proliferating in the dental implant internal cavity, frequently lead to implant failure. Reduction in implant bacterial load may result in a shift of the composition of the microbiome in favor of less pathogenic species, potentially improving dental implant success rates, reducing surgical revisions, and associated cost savings. This study aims to determine how disinfectant gel (hydrogen peroxide or chlorhexidine) insertion into dental implant internal cavities affects implant failure rates, bacterial load and microbiome composition.",[135,136,28,137],"Peri-Implantitis","Peri-implant Mucositis","Dental Implant Failed","2024-12-19",{"date":140,"type":33},"2024-12-27",{"date":142,"type":33},"2022-07-28",{"date":144,"type":22},"2025-11",{"name":146,"class":147},"Madigan Army Medical Center","FED"]